TCT 2025: ENCIRCLE Trial Outcomes
The Medical Dialogues Bureau reports from the TCT Conference 2025 in San Francisco, USA, on the outcomes of the ENCIRCLE trial.
Percutaneous transseptal mitral valve replacement (TMVR) with the SAPIEN M3 System has shown significant reductions in mitral regurgitation (MR) severity, improvements in functional status and quality of life, and low mortality and heart failure hospitalization rates at one year.
According to results from the ENCIRCLE trial presented by Dr. John Webb on behalf of the ENCIRCLE investigators at TCT 2025.
The ENCIRCLE trial is a pivotal study evaluating outcomes of a fully percutaneous, transseptal TMVR system in patients with symptomatic MR who are not suitable candidates for surgery or other commercially available transcatheter treatment options.
Author's summary: TCT 2025 presents ENCIRCLE trial outcomes.
More News
- NOTICE CITY OF WARWICK PUBLIC HEARING - Cranston Herald
- This Day That Year: Revisiting Gulzar’s Maachis
- V Levels must build on the best of BTECs, not erase them
- Warwick Corridor’s $102M facelift - Warwick Beacon
- V levels can streamline, but beware a re-badging exercise
- Senate reconvenes after fall break
- The billionaire loophole: How Canada’s tax system fuels inequality
- COLUMN: MP Matt Western talks Warwick Mop and V-Levels